Profile data is unavailable for this security.
About the company
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. Its lead therapeutic agent, vodobatinib (SCC-138), is a c-ABL inhibitor that has the potential to be a therapy modulating cellular homeostasis in neurodegenerative diseases. Vibozilimod (SCD-044) is a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist targeting autoimmune disorders. SCD-153 is a topical agent being developed for the treatment of alopecia areata. SBO-154 is an ADC being developed for multiple tumor types expressing MUC-1.
- Revenue in INR (TTM)684.05m
- Net income in INR-3.89bn
- Incorporated2006
- Employees409.00
- LocationSun Pharma Advanced Research Co Ltd17B Mahal Industrial EstateMahakali Caves Road, Andheri (East)MUMBAI 400093IndiaIND
- Phone+91 2 266455645
- Fax+91 2 266455685
- Websitehttps://www.sparc.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gufic BioSciences Ltd | 8.14bn | 863.69m | 39.36bn | 1.45k | 45.13 | -- | 38.04 | 4.83 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Innova Captab Ltd | 11.42bn | 1.06bn | 41.36bn | -- | 30.51 | -- | 33.29 | 3.62 | 23.69 | 23.69 | 236.62 | -- | -- | -- | -- | -- | -- | 10.82 | -- | 18.38 | 33.38 | 25.18 | 9.30 | 8.04 | -- | 8.89 | -- | -- | 16.72 | 24.90 | 38.84 | 36.55 | 104.14 | -- |
| Hikal Ltd | 18.03bn | 677.82m | 41.87bn | 2.06k | 61.80 | -- | 22.10 | 2.32 | 5.49 | 5.49 | 145.97 | -- | -- | -- | -- | 8,749,879.00 | -- | 5.07 | -- | 7.51 | 53.06 | 46.78 | 3.76 | 5.86 | -- | 2.45 | -- | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| RPG Life Sciences Limited | 6.00bn | 923.20m | 45.74bn | 1.27k | 49.54 | -- | 41.41 | 7.63 | 55.82 | 55.82 | 362.60 | -- | -- | -- | -- | 4,721,969.00 | -- | 16.07 | -- | 21.77 | 68.42 | 62.99 | 15.39 | 11.99 | -- | 220.43 | -- | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Aarti Drugs Ltd | 24.23bn | 1.57bn | 46.55bn | 1.06k | 29.86 | -- | 22.26 | 1.92 | 17.08 | 17.08 | 263.82 | -- | -- | -- | -- | 22,770,740.00 | -- | 9.73 | -- | 15.78 | 34.32 | 22.23 | 6.48 | 8.25 | -- | 7.28 | -- | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Unichem Laboratories Ltd | 17.28bn | -605.50m | 47.11bn | 3.19k | -- | -- | 90.17 | 2.73 | -8.59 | -8.59 | 245.15 | -- | -- | -- | -- | 5,410,587.00 | -- | -1.67 | -- | -2.03 | 62.00 | 56.18 | -3.50 | -3.99 | -- | 0.1401 | -- | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
| Supriya Lifescience Ltd | 5.99bn | 1.35bn | 47.18bn | 448.00 | 34.90 | -- | 31.09 | 7.88 | 16.80 | 16.80 | 74.42 | -- | -- | -- | -- | 13,370,000.00 | -- | 19.08 | -- | 24.04 | 62.75 | 57.12 | 22.58 | 24.71 | -- | 92.47 | -- | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| SeQuent Scientific Ltd | 14.27bn | 54.87m | 48.19bn | 1.20k | 905.27 | -- | 62.04 | 3.38 | 0.2137 | 0.2137 | 57.18 | -- | -- | -- | -- | 11,939,190.00 | -- | 1.09 | -- | 1.76 | 45.38 | 41.97 | 0.9902 | 1.18 | -- | 0.9009 | -- | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Morepen Laboratories Ltd | 17.45bn | 1.18bn | 48.74bn | 1.62k | 38.49 | -- | 32.57 | 2.79 | 2.31 | 2.31 | 34.26 | -- | -- | -- | -- | 10,749,300.00 | -- | 7.90 | -- | 13.34 | 37.86 | 33.34 | 6.77 | 5.49 | -- | 33.34 | -- | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Aarti Pharmalabs Ltd | 19.50bn | 2.25bn | 55.29bn | 1.63k | 24.54 | -- | 18.34 | 2.84 | 24.86 | 24.86 | 215.17 | -- | -- | -- | -- | 11,983,730.00 | -- | -- | -- | -- | 44.20 | -- | 11.55 | -- | -- | 18.55 | -- | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Sun Pharma Advanced Research Co Ltd | 684.05m | -3.89bn | 66.90bn | 409.00 | -- | -- | -- | 97.79 | -11.97 | -11.97 | 2.11 | -- | -- | -- | -- | 1,672,501.00 | -- | -61.70 | -- | -119.31 | 59.81 | 74.49 | -568.24 | -163.40 | -- | -208.33 | -- | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Orchid Pharma Ltd | 8.81bn | 1.12bn | 70.31bn | 872.00 | 60.57 | -- | 47.98 | 7.98 | 22.89 | 22.89 | 180.65 | -- | -- | -- | -- | 10,101,540.00 | -- | -0.9734 | -- | -1.40 | 40.67 | 40.74 | 12.78 | -2.40 | -- | 6.08 | -- | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Shilpa Medicare Ltd | 11.84bn | 447.57m | 84.20bn | 931.00 | 172.37 | -- | 55.01 | 7.11 | 5.00 | 5.00 | 133.55 | -- | -- | -- | -- | 12,716,850.00 | -- | 2.84 | -- | 3.65 | 65.19 | 60.08 | 3.79 | 7.03 | -- | 1.56 | -- | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Blue Jet Healthcare Ltd | 6.95bn | 1.57bn | 86.75bn | 447.00 | 55.10 | -- | 47.42 | 12.48 | 9.08 | 9.08 | 40.07 | -- | -- | -- | -- | 15,547,110.00 | -- | -- | -- | -- | 55.54 | -- | 22.65 | -- | -- | 124.37 | -- | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Procter & Gamble Health Ltd | 11.51bn | 2.01bn | 88.01bn | 1.41k | 43.81 | 16.35 | 38.54 | 7.64 | 121.01 | 121.01 | 693.20 | 324.24 | 1.21 | 2.71 | 11.45 | -- | 21.21 | -- | 29.28 | -- | 71.29 | -- | 17.46 | -- | 1.90 | 386.94 | 0.0175 | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| F D C Ltd | 20.45bn | 3.14bn | 88.28bn | 6.66k | 28.22 | -- | 24.83 | 4.32 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
Data as of Oct 11 2024. Currency figures normalised to Sun Pharma Advanced Research Co Ltd's reporting currency: Indian Rupee INR
1.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Jul 2024 | 2.32m | 0.72% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 1.64m | 0.51% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 620.84k | 0.19% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 398.79k | 0.12% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 373.76k | 0.12% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Jun 2024 | 87.57k | 0.03% |
| TIAA-CREF Investment Management LLCas of 30 Jun 2024 | 60.59k | 0.02% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Jul 2024 | 56.29k | 0.02% |
| SBI Funds Management Ltd.as of 30 Jun 2024 | 49.79k | 0.02% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jul 2024 | 36.78k | 0.01% |
More ▼
Data from 31 Dec 2023 - 08 Aug 2024Source: FactSet Research Systems Inc.
